Helen Tran, PharmaD

Medical Director
Pfizer Inc, New York, NY, USA

Poster(s):

• (97) A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe alopecia areata
  Wednesday, October 29, 2025

• (99) Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: 3-year results from the ALLEGRO-LT phase 3, open-label study
  Wednesday, October 29, 2025